Laurus Labs Share Price, Fundamentals and Financials

Laurus Labs is an Indian pharmaceutical and biotechnology company engaged in APIs, generic finished dosage forms, contract development and manufacturing, biotechnology and selected speciality ingredients.

The company is commonly analysed through Generics, CDMO or Synthesis, and Bio or fermentation-led businesses. Verify current segment reporting from the latest company presentation.

It earns revenue from APIs, finished dosage products, custom molecules, process development, scale-up, commercial manufacturing and biotechnology services for pharmaceutical customers.

CDMO can provide complex, longer-duration customer projects and potentially better margins. Project timing, approvals and customer demand can still make revenue uneven.

Laurus Labs has historical strength in antiretroviral APIs and formulations and works across oncology, cardiovascular, diabetes, CNS and other areas, alongside custom synthesis and newer technology platforms.

Monitor CDMO execution, API pricing, formulation volumes, EBITDA margin, new-capacity utilisation, research spending, capital expenditure, net debt, regulatory inspections and customer concentration.

Risks include regulatory observations, customer concentration, pricing pressure, project delays, high capital expenditure, currency changes, raw-material volatility and execution risk in new technologies.

Laurus Labs has paid dividends in the past. Dividend amount and timing can change, so verify the latest record date and ex-date from NSE, BSE and company filings.

Public corporate-action history shows a face-value split from ₹10 to ₹2 in 2020 and no widely reported bonus issue. Confirm the latest position from official filings.

The NSE symbol is LAURUSLABS, the BSE scrip code is 540222, and the Yahoo Finance-compatible NSE symbol is LAURUSLABS.NS.

Use the chart to understand direction and volatility, but combine it with financial performance, valuation, business quality and risk factors rather than relying on short-term price movement alone.

Common comparisons include Divi’s Laboratories, Syngene International, Aurobindo Pharma and Dr. Reddy’s Laboratories. The most relevant peer depends on the business segment being compared.

No. Generics remain important, but the company has expanded into CDMO, biotechnology, fermentation, peptides and advanced therapy-related capabilities.

Use the company investor-relations website, NSE and BSE filings, audited annual reports, quarterly results and shareholding-pattern disclosures.